

NCIC CLINICAL TRIALS GROUP

GASTROINTESTINAL

DISEASE SITE COMMITTEE MEETING
AGENDA

Delta Chelsea Hotel, Toronto
Sunday, October 19, 2003 - 9:00 a.m. - 3:30 p.m.
Room: Churchill Ballroom A

Chair: Dr. Malcolm Moore

9:00 am	WELCOME AND INTRODUCTION	Dr. T. Fields
9:05 am	CLOSED TRIALS: BRIEF COMMENTS	Dr. T. Fields / Dr. C. O'Callaghan
9:20 am	ACTIVE TRIALS CO.16 CO.17 ES.2 PA.2	Dr. J. Couture Dr. D. Jonker Dr. Rebecca Wong Dr. S. Gallinger
10:10 am	IND TRIALS UPDATE Update from IND Committee Meeting + Discussion of Future GI IND Trials	Dr. Ralph Wong
10:30 am	REFRESHMENT BREAK	
10:50 am	CONDUCTING CTSU TRIALS IN CANADA	CTSU Representative
11:10 am	CTSU TRIALS ENDORSED BY NCIC CTG PAC.1: (SWOG-S0205) – A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer	Dr. Ralph Wong
	GAC.1: (CALGB-80101) – A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma	Dr. G. Bjarnason
11:35 am	CTSU STUDIES FOR CONSIDERATION How to determine CTSU endorsement and participation? - General Discussion	Dr C. O'Callaghan / Dr. M. Moore

continued . . .

12:00 pm	LUNCH	
1:00 pm	PROSPECTIVE NCIC CTG TRIALS	
	Multi-institutional randomized phase III Trial of Gemcitabine plus Capecitabine (GemCap) vs Gemcitabine alone in advanced unresectable biliary cancer	Dr. J. Knox
	A phase III randomized 2 x 2 factorial trial of early post-op RT vs standard timing of RT, with the addition of Avastin to bolus 5FU, in stage II-III rectal carcinoma patients not having pre-op RT	Dr. F. Perera / Dr. C. Leighton
	Randomized phase II trial of XELOX (capecitabine plus oxaliplatin) vs XELIRI (capecitabine plus irinotecan) in patients with recurrent or metastatic esophageal, gastroesophageal junction or gastric adenocarcinoma or undifferentiated carcinoma	Dr. L. Siu
	Canadian Uncommon Cancer Initiative (CUCI)	Dr. P. Czaykowski
	Phase II study of neoadjuvant 5-FU + Leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma	Dr. O. Bathe
	A randomized placebo controlled trial assessing Sandostatin LAR for diarrhea control in the adjuvant treatment of rectal cancer	Dr J. Kamra
	EGFR and VEGF inhibition in metastatic hepatoma	Dr. C. Cripps
	Late additions...	
2:10 pm	GI INTERGROUP UPDATE	
	Overview	Dr. M. Moore
	Colon Task Force	Dr. T. Fields / Dr. M. Moore
	Esophageal Task Force	Dr. Rebecca Wong
	Rectal Task Force	Dr. J. Brierly
	Pancreas Task Force	Dr. M. Moore
2:30 pm	REFRESHMENT BREAK	
2:50 PM	ACTIVITIES OF THE GI DISEASE SITE COMMITTEE	Dr. M. Moore
3:00 pm	DISCUSSION SESSION Oxaliplatin in Canada	Dr. M. Moore
3:30 pm	CLOSING REMARKS & ADJOURNMENT	Dr. M. Moore
3:35 pm	CLOSED SESSION: GI EXECUTIVE MEETING	Dr. M. Moore
4:30 pm	ADJOURNMENT	